GSK PLC ADR (GSK): Price and Financial Metrics
GSK Price/Volume Stats
Current price | $36.09 | 52-week high | $39.74 |
Prev. close | $35.89 | 52-week low | $29.76 |
Day low | $35.84 | Volume | 1,318,694 |
Day high | $36.25 | Avg. volume | 3,380,429 |
50-day MA | $35.74 | Dividend yield | 3.9% |
200-day MA | $35.44 | Market Cap | 73.89B |
GSK Stock Price Chart Interactive Chart >
GSK POWR Grades
- Value is the dimension where GSK ranks best; there it ranks ahead of 97.45% of US stocks.
- GSK's strongest trending metric is Growth; it's been moving up over the last 177 days.
- GSK's current lowest rank is in the Momentum metric (where it is better than 9.57% of US stocks).
GSK Stock Summary
- GSK has a market capitalization of $70,052,400,000 -- more than approximately 96.83% of US stocks.
- With a price/earnings ratio of 3.83, GSK PLC P/E ratio is greater than that of about just 6.67% of stocks in our set with positive earnings.
- In terms of volatility of its share price, GSK is more volatile than just 2.86% of stocks we're observing.
- Stocks that are quantitatively similar to GSK, based on their financial statements, market capitalization, and price volatility, are STLA, GILD, CMI, NTES, and MCHP.
- Visit GSK's SEC page to see the company's official filings. To visit the company's web site, go to www.gsk.com.
GSK PLC ADR (GSK) Company Bio
GSK plc, formerly GlaxoSmithKline plc, is a British multinational pharmaceutical and biotechnology company with global headquarters in London, England. Established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham. GSK is the tenth largest pharmaceutical company and #294 on the 2022 Fortune Global 500, ranked behind other pharmaceutical companies China Resources, Sinopharm, Johnson & Johnson, Pfizer, Roche, AbbVie, Novartis, Bayer, and Merck. (Source:Wikipedia)
Latest GSK News From Around the Web
Below are the latest news stories about GSK PLC that investors may wish to consider to help them evaluate GSK as an investment opportunity.
7 ‘Smart Money’ Stocks Set to Explode HigherInvest like the pros by wagering on these top seven smart money stocks to buy at this time, offering tremendous upside ahead. |
Amazon Health: A long play and a search for partnersAmazon Pharmacy is just one of the segments of health that the e-retail giant is pursuing. |
Best Dividend Stocks: British Giant GSK Offers Yield, Security For InvestorsIn this week's IBD Income Investor, British pharmaceutical giant GSK is in focus. Headquartered in London, GSK is a pharmaceutical company responsible for developing an abundance of drugs. In the biotech sector this yield is especially appealing considering the majority of companies do not pay a dividend at all. |
Incyte (INCY) Down on FDA Nod for Another Myelofibrosis DrugIncyte (INCY) declines on potential competition for lead drug Jakafi from Ojjaara for the treatment of intermediate or high-risk myelofibrosis. |
FDA approves GSK drug Ojjaara for myelofibrosis with anemiaMore on GSK |
GSK Price Returns
1-mo | N/A |
3-mo | 6.95% |
6-mo | N/A |
1-year | 22.23% |
3-year | 11.66% |
5-year | 14.97% |
YTD | 5.76% |
2022 | -16.73% |
2021 | 26.64% |
2020 | -17.79% |
2019 | 29.12% |
2018 | 13.70% |
GSK Dividends
Ex-Dividend Date | Type | Payout Amount | Change | ||||||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
Continue Researching GSK
Here are a few links from around the web to help you further your research on Glaxosmithkline Plc's stock as an investment opportunity:Glaxosmithkline Plc (GSK) Stock Price | Nasdaq
Glaxosmithkline Plc (GSK) Stock Quote, History and News - Yahoo Finance
Glaxosmithkline Plc (GSK) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...